Back

Zenkuda and tabirafusp-ted meet primary endpoints in pivotal DAYBREAK trial

Verifying
  • Zenkuda and tabirafusp-ted met primary endpoints in the pivotal DAYBREAK trial.
  • Most Zenkuda patients reached a 24-week dosing interval under retreatment criteria.
  • The trial evaluated both treatments in wet age-related macular degeneration.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.